71 related articles for article (PubMed ID: 15451429)
1. Pharmacological activity of DTPA linked to protein-based drug carrier systems.
Michaelis M; Langer K; Arnold S; Doerr HW; Kreuter J; Cinatl J
Biochem Biophys Res Commun; 2004 Oct; 323(4):1236-40. PubMed ID: 15451429
[TBL] [Abstract][Full Text] [Related]
2. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells.
Ulbrich K; Michaelis M; Rothweiler F; Knobloch T; Sithisarn P; Cinatl J; Kreuter J
Int J Pharm; 2011 Mar; 406(1-2):128-34. PubMed ID: 21185364
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
[TBL] [Abstract][Full Text] [Related]
4. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activities of four chelating agents against human neuroblastoma cells.
Shen L; Zhao HY; Du J; Wang F
In Vivo; 2005; 19(1):233-6. PubMed ID: 15796180
[TBL] [Abstract][Full Text] [Related]
6. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.
Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K
J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904
[TBL] [Abstract][Full Text] [Related]
7. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy.
Acharya S; Dilnawaz F; Sahoo SK
Biomaterials; 2009 Oct; 30(29):5737-50. PubMed ID: 19631377
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
9. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells.
Azarmi S; Huang Y; Chen H; McQuarrie S; Abrams D; Roa W; Finlay WH; Miller GG; Löbenberg R
J Pharm Pharm Sci; 2006; 9(1):124-32. PubMed ID: 16849014
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
11. Surfactant-polymer nanoparticles enhance the effectiveness of anticancer photodynamic therapy.
Khdair A; Gerard B; Handa H; Mao G; Shekhar MP; Panyam J
Mol Pharm; 2008; 5(5):795-807. PubMed ID: 18646775
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells.
Kohler N; Sun C; Wang J; Zhang M
Langmuir; 2005 Sep; 21(19):8858-64. PubMed ID: 16142971
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
Blaheta RA; Michaelis M; Natsheh I; Hasenberg C; Weich E; Relja B; Jonas D; Doerr HW; Cinatl J
Br J Cancer; 2007 Jun; 96(11):1699-706. PubMed ID: 17505515
[TBL] [Abstract][Full Text] [Related]
14. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
15. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
16. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
17. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin.
Di Stefano G; Fiume L; Baglioni M; Busi C; Chieco P; Kratz F; Mattioli A
Eur J Pharm Sci; 2007 Feb; 30(2):136-42. PubMed ID: 17218086
[TBL] [Abstract][Full Text] [Related]
18. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.
Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173
[TBL] [Abstract][Full Text] [Related]
19. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
Akbas SH; Timur M; Ozben T
J Surg Res; 2005 May; 125(1):49-55. PubMed ID: 15836850
[TBL] [Abstract][Full Text] [Related]
20. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
